Safety, Tolerability, and Pharmacokinetics of RCS-21 in Healthy Volunteers. (AMIR-21)
Safety, Tolerability and Pharmacokinetics of Single-ascending Doses of RCS-21 in Healthy Volunteers. A Double Blind, Randomized, Placebo Controlled Phase I Study.
Sponsor: LungenClinic Grosshansdorf
A PHASE1 clinical study on Healthy Volunteers and Pharmacokinetics, this trial is actively recruiting participants. The trial is conducted by LungenClinic Grosshansdorf and has accumulated 5 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Dec 2025 — Present [monthly]
Recruiting PHASE1
-
Sep 2025 — Dec 2025 [monthly]
Recruiting PHASE1
-
Jun 2025 — Sep 2025 [monthly]
Recruiting PHASE1
-
Apr 2025 — Jun 2025 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Feb 2025 — Apr 2025 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- LungenClinic Grosshansdorf
- RNATICS GmbH
For direct contact, visit the study record on ClinicalTrials.gov .